Authors

• Ingrid Menkyová
• Dana Horáková (ORCID: https://orcid.org/0000-0003-1915-0036)
• Tomáš Uher (ORCID: https://orcid.org/0000-0003-3160-9022)
• Jan Krásenský (ORCID: https://orcid.org/0000-0002-5605-8821)
• Jaroslav Lindner (ORCID: https://orcid.org/0000-0001-8432-4069)
• Niels Bergsland (ORCID: https://orcid.org/0000-0002-7792-0433)
• Petra Nytrová (ORCID: https://orcid.org/0000-0003-4885-602X)
• Dominika Šťastná (ORCID: https://orcid.org/0000-0003-2418-4847)
• Miguel D’haeseleer (ORCID: https://orcid.org/0000-0003-4378-0089)
• Eva Havrdová (ORCID: https://orcid.org/0000-0002-9543-4359)
• Václav Čapek (ORCID: https://orcid.org/0000-0002-8574-7001)
• Eliza Varju
• Manuela Vaněčková (ORCID: https://orcid.org/0000-0001-6895-3738)

Institutions

• National Multiple Sclerosis Society (US)
• Vrije Universiteit Brussel (BE)
• Slovak Medical University (SK)
• Charles University (CZ)
• Copenhagen University Hospital (DK)
• Rigshospitalet (DK)
• Belgian Nuclear Research Centre (BE)
• Don Carlo Gnocchi Foundation (IT)
• Universitair Ziekenhuis Brussel (BE)
• Danish Multiple Sclerosis Center (DK)
• General University Hospital in Prague (CZ)
• National MS Center Melsbroek
• University at Buffalo, State University of New York (US)

Publication Details

Journal

Annals of Clinical and Translational Neurology

Published

2025-05-29

DOI

https://doi.org/10.1002/acn3.70091

Citations

1

Primary Topic

Multiple Sclerosis Research Studies

Type

article

Field-Weighted Citation Impact

1.47

Funders

• Bristol-Myers Squibb
• Pfizer
• Sanofi
• Biogen
• Teva Pharmaceutical Industries
• Univerzita Karlova v Praze
• European Commission
• Sanofi Genzyme
• Cilag